FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Apellis Pharma NDA Review Extended on New Data

FDA extends by three months its review of an Apellis Pharmaceuticals NDA for intravitreal pegcetacoplan based on new data submitted that the agency ha...

latest-news-card-1
Medical Devices

New MDIC Framework on Device Trials

The Medical Device Innovation Consortium releases a new framework that outlines a systematic approach for patient-focused clinical trial designs.

latest-news-card-1
Human Drugs

21 State AGs Urge FDA OK of OTC Birth Control

Twenty-one state attorneys general urge FDA to approve over-the-counter birth control pills.

latest-news-card-1
Medical Devices

Exactechs TriVerse Knee System Cleared

FDA clears an Exactech 510(k) for its TriVerse primary knee system.

latest-news-card-1
Human Drugs

Lifting Barriers to Transgender People in Cancer Trials

FDA and academic researchers present a framework to include transgender people in clinical trials.

latest-news-card-1
Medical Devices

Safety Alert on Infant Head Shaping Pillows

FDA issues a safety alert warning parents and caregivers not to use infant head shaping pillows intended to change an infants head shape or symmetry. ...

latest-news-card-1
Human Drugs

Panel OKs CDER Quality Management Maturity Program

FDAs Pharmaceutical Science and Clinical Pharmacology Advisory Committee unanimously votes to recommend that CDER move forward with developing and imp...

latest-news-card-1
Human Drugs

Califf Touts Progress in Drug Compounding Oversight

FDA commissioner Robert Califf says FDA and its state and federal partners have made great progress in oversight of drug compounding, but there are st...

latest-news-card-1
Human Drugs

Updated Meeting Definitions

FDA posts updated definitions of face-to-face meeting formats to the PDUFA 7 and BsUFA 3 Web pages.

latest-news-card-1
Federal Register

Guidance on Oncology Cross-Labeling

Federal Register notice: FDA makes available a final guidance entitled Cross Labeling Oncology Drugs in Combination Regimens.